Stefan Michiels

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5728225/publications.pdf

Version: 2024-02-01

319 papers	25,860 citations	10373 72 h-index	7152 153 g-index
339 all docs	339 docs citations	339 times ranked	30122 citing authors

#	Article	IF	Citations
1	A twoâ€stage dropâ€theâ€losers design for timeâ€toâ€event outcome using a historical control arm. Pharmaceutical Statistics, 2022, 21, 268-288.	0.7	0
2	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. Npj Breast Cancer, 2022, 8, 3.	2.3	33
3	Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. Annals of Oncology, 2022, 33, 434-444.	0.6	12
4	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. Journal of Clinical Oncology, 2022, 40, 1111-1123.	0.8	23
5	A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. Trials, 2022, 23, 193.	0.7	9
6	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. Journal of Clinical Oncology, 2022, 40, 2148-2162.	0.8	18
7	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. Journal of Clinical Oncology, 2022, 40, 2361-2374.	0.8	45
8	Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France. JAMA Network Open, 2022, 5, e225118.	2.8	9
9	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. Journal of Clinical Oncology, 2022, 40, 3190-3204.	0.8	23
10	Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer. BMC Cancer, 2022, 22, 526.	1.1	10
11	Complex Disease Individual Molecular Characterization Using Infinite Sparse Graphical Independent Component Analysis. Cancer Informatics, 2022, 21, 117693512211057.	0.9	3
12	Informing the development of multidisciplinary interventions to help breast cancer patients return to work: a qualitative study. Supportive Care in Cancer, 2022, 30, 8287-8299.	1.0	4
13	Axillary reverse mapping using near-infrared fluorescence imaging in invasive breast cancer (ARMONIC) Tj ETQq1 1 0.784314 rgBT /Over	0.5	5
14	Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions. Annals of Surgical Oncology, 2021, 28, 2138-2145.	0.7	5
15	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. Translational Lung Cancer Research, 2021, 10, 826-838.	1.3	5
16	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 1653-1665.	1.3	8
17	Biomarker Discovery and Validation: Statistical Considerations. Journal of Thoracic Oncology, 2021, 16, 537-545.	0.5	66
18	Assessing the risk of severe post-treatment (tx) cancer-related fatigue (CRF) among breast cancer survivors (BCS) in the CANcer TOxicity (CANTO) cohort.. Journal of Clinical Oncology, 2021, 39, 12022-12022.	0.8	0

#	Article	IF	Citations
19	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma.. Journal of Clinical Oncology, 2021, 39, 4067-4067.	0.8	1
20	Impact of COVID-19 on healthcare organisation and cancer outcomes. European Journal of Cancer, 2021, 153, 123-132.	1.3	25
21	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. Cancer Cell, 2021, 39, 1039-1041.	7.7	2
22	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. Cancers, 2021, 13, 4910.	1.7	8
23	Determinants of use of oral complementary-alternative medicine among women with early breast cancer:Âa focus on cancer-related fatigue. Breast Cancer Research and Treatment, 2021, 190, 517-529.	1.1	9
24	The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Annals of Oncology, 2021, 32, 1236-1244.	0.6	109
25	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. European Journal of Cancer, 2021, 157, 278-290.	1.3	8
26	Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk. Scientific Reports, 2021, 11, 19884.	1.6	3
27	Penalized Poisson model for network metaâ€analysis of individual patient timeâ€toâ€event data. Statistics in Medicine, 2021, 41, 340.	0.8	4
28	A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier. PLoS ONE, 2021, 16, e0259121.	1.1	3
29	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	2.3	112
30	Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 98-110.	2.3	3
31	Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies. Breast Cancer Research and Treatment, 2020, 179, 387-401.	1.1	9
32	Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. Statistical Methods in Medical Research, 2020, 29, 1483-1498.	0.7	2
33	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clinical Cancer Research, 2020, 26, 242-255.	3.2	114
34	Qualityâ€ofâ€life assessment in French patients with metastatic melanoma in real life. Cancer, 2020, 126, 611-618.	2.0	12
35	Reactive stroma and trastuzumab resistance in HER2â€positive early breast cancer. International Journal of Cancer, 2020, 147, 266-276.	2.3	13
36	Metaâ€analysis of clinical trials with competing timeâ€toâ€event endpoints. Biometrical Journal, 2020, 62, 712-723.	0.6	1

#	Article	IF	Citations
37	Prediction of Breast Cancer Treatmentâ€"Induced Fatigue by Machine Learning UsingÂGenome-Wide Association Data. JNCI Cancer Spectrum, 2020, 4, pkaa039.	1.4	9
38	Predictive classifier for intensive treatment of head and neck cancer. Cancer, 2020, 126, 5263-5273.	2.0	11
39	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2020, 31, 1491-1505.	0.6	658
40	Body weight and return to work among survivors of early-stage breast cancer. ESMO Open, 2020, 5, e000908.	2.0	9
41	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. Npj Precision Oncology, 2020, 4, 27.	2.3	16
42	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nature Communications, 2020, 11, 6335.	5.8	46
43	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer, 2020, 6, 15.	2.3	16
44	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E nonâ€"small cell lung cancer. European Journal of Cancer, 2020, 132, 211-223.	1.3	53
45	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16.	2.3	90
46	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106
47	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. Journal of Clinical Oncology, 2020, 38, 2762-2772.	0.8	80
48	Integrating expertâ€™s knowledge constraint of time dependent exposures in structure learning for Bayesian networks. Artificial Intelligence in Medicine, 2020, 107, 101874.	3.8	6
49	A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. ERJ Open Research, 2020, 6, 00174-2019.	1.1	3
50	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase InhibitorsÂinÂPatients With NSCLC: A Brief Report. JTO Clinical and Research Reports, 2020, 1, 100023.	0.6	11
51	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€L1 and TILs as immunoâ€oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	2.1	142
52	Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models. BMC Bioinformatics, 2020, 21, 277.	1.2	11
53	Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. Breast, 2020, 52, 23-32.	0.9	15
54	On the Use of Neural Networks with Censored Time-to-Event Data. Lecture Notes in Computer Science, 2020, , 56-67.	1.0	3

#	Article	IF	Citations
55	Abstract 1867: Characterization of multiple driver alterations in acquired resistance to osimertinib inEGFR-mutated lung cancer: implementation of single cell approaches. , 2020, , .		1
56	Development and Validation of Risk Prediction Models. , 2020, , 1-22.		1
57	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2020, 38, e21080-e21080.	0.8	0
58	Abstract P4-10-16: Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. , 2020, , .		0
59	Use of oral complementary-alternative medicine (OCAM) and fatigue among early breast cancer (BC) patients (pts). European Journal of Cancer, 2020, 138, S92.	1.3	0
60	EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. European Journal of Cancer, 2019, 117, 60-68.	1.3	68
61	Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy. Annals of Oncology, 2019, 30, v55.	0.6	3
62	OC-0153 Immune infiltrate modulation induced by preoperative radiotherapy in breast cancer patients. Radiotherapy and Oncology, 2019, 133, S73-S74.	0.3	0
63	Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Annals of Oncology, 2019, 30, 1784-1795.	0.6	138
64	An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error. Contemporary Clinical Trials Communications, 2019, 15, 100402.	0.5	1
65	EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. Annals of Oncology, 2019, 30, ii7.	0.6	2
66	Fatigue and physical activity in cancer survivors: A crossâ€sectional populationâ€based study. Cancer Medicine, 2019, 8, 2535-2544.	1.3	26
67	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	0.8	505
68	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptorâ€"Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1169-1178.	0.8	266
69	Overestimated treatment effects in randomised phase II trials: What's up doctor?. European Journal of Cancer, 2019, 123, 116-117.	1.3	2
70	Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Annals of Oncology, 2019, 30, 1941-1949.	0.6	155
71	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Annals of Oncology, 2019, 30, 236-242.	0.6	123
72	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 2019, 134, 39-45.	2.0	200

#	Article	IF	Citations
73	A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. Statistical Methods in Medical Research, 2019, 28, 170-183.	0.7	12
74	Abstract CT081: Pediatric precision medicine program in recurrent tumors: Results of the first 500 patients included in the European MAPPYACTS molecular profiling trial. Cancer Research, 2019, 79, CT081-CT081.	0.4	3
75	Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.. Journal of Clinical Oncology, 2019, 37, 10018-10018.	0.8	3
76	Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.. Journal of Clinical Oncology, 2019, 37, 512-512.	0.8	2
77	Abstract P1-15-03: Association between exercise, pathological complete response, and treatment tolerability in patients receiving neoadjuvant chemotherapy for operable breast cancer: Results from the CANTO study. , 2019, , .		0
78	Abstract PD5-06: The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer. , 2019, , .		0
79	Abstract 311: Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer. , 2019, , .		0
80	Abstract 318: Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study. , 2019, , .		0
81	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 560-567.	3.0	206
82	Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death. Statistics in Medicine, 2018, 37, 2148-2161.	0.8	7
83	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. European Journal of Cancer, 2018, 92, 1-10.	1.3	14
84	surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials. Computer Methods and Programs in Biomedicine, 2018, 155, 189-198.	2.6	29
85	A benchmark study of scoring methods for non-coding mutations. Bioinformatics, 2018, 34, 1635-1641.	1.8	21
86	biospear: an R package for biomarker selection in penalized Cox regression. Bioinformatics, 2018, 34, 112-113.	1.8	16
87	The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Annals of Oncology, 2018, 29, 30-35.	0.6	118
88	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research, 2018, 24, 2517-2529.	3.2	26
89	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Annals of Oncology, 2018, 29, 162-169.	0.6	46
90	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology, 2018, 52, 16-25.	4.3	303

#	Article	IF	Citations
91	Steps forward for cancer precision medicine. Nature Reviews Drug Discovery, 2018, 17, 1-2.	21.5	37
92	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncology, The, 2018, 19, 27-39.	5.1	717
93	Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study. Oncotarget, 2018, 9, 1906-1914.	0.8	13
94	QL4 - ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH METASTATIC MELANOMA IN REAL CLINICAL PRACTICE IN FRANCE. Value in Health, 2018, 21, S13.	0.1	0
95	Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study. Annals of Oncology, 2018, 29, viii620-viii621.	0.6	0
96	Assessment of quality of life in patients with metastatic melanoma in real clinical practice in France. Annals of Oncology, 2018, 29, viii460.	0.6	0
97	Neuropathy and health behaviors in cancer survivors treated with chemotherapy (CT). Annals of Oncology, 2018, 29, viii604.	0.6	0
98	Tumor Mutation Burden as a Biomarker in Resected Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2995-3006.	0.8	223
99	Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. Journal of Clinical Oncology, 2018, 36, 981-990.	0.8	95
100	Breast cancer (BC) related fatigue: A longitudinal investigation of its prevalence, domains and correlates. Annals of Oncology, 2018, 29, viii605.	0.6	3
101	Physical activity (PA) and patterns of quality of life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC). Annals of Oncology, 2018, 29, viii755.	0.6	0
102	Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial. Annals of Oncology, 2018, 29, viii378-viii379.	0.6	0
103	Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC). Annals of Oncology, 2018, 29, viii621.	0.6	0
104	Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial. Annals of Oncology, 2018, 29, viii667.	0.6	0
105	P3.03-27 Somatic BRCA1/2 Mutations in Advanced NSCLC Patients: Description of a Sub-Population from the Ongoing Unicancer SAFIR02-Lung / IFCT-1301 Trial. Journal of Thoracic Oncology, 2018, 13, S920-S921.	0.5	0
106	Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort. Annals of Oncology, 2018, 29, viii704.	0.6	4
107	Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays. PLoS ONE, 2018, 13, e0203346.	1.1	4
108	Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. European Journal of Cancer, 2018, 105, 33-40.	1.3	38

#	Article	IF	Citations
109	Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?. European Journal of Cancer, 2018, 103, 108-119.	1.3	18
110	Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 416-427.	1.3	11
111	PO-0741: Implementation of contouring guidelines can be achieved by online learning through a dummy run. Radiotherapy and Oncology, 2018, 127, S380-S381.	0.3	0
112	Robotic Prophylactic Nipple-Sparing Mastectomy with Immediate Prosthetic Breast Reconstruction: A Prospective Study. Annals of Surgical Oncology, 2018, 25, 2579-2586.	0.7	73
113	Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology. Computational and Mathematical Methods in Medicine, 2018, 2018, 1-8.	0.7	8
114	Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting. BMC Medical Research Methodology, 2018, 18, 67.	1.4	2
115	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Seminars in Cancer Biology, 2018, 52, 151-157.	4.3	108
116	All simulation models of breast cancer are wrong but some are useful. The Lancet Global Health, 2018, 6, e818-e819.	2.9	0
117	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. Cancer Journal (Sudbury, Mass), 2018, 24, 153-162.	1.0	17
118	Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Annals of Oncology, 2018, 29, 1755-1762.	0.6	42
119	Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer. , 2018, , .		4
120	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of â€œindolentâ€•stage IV disease (Stage IV_{indolent}).. Journal of Clinical Oncology, 2018, 36, 1019-1019.	0.8	3
121	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750.	0.8	12
122	Development and Validation of Genomic Signatures. , 2018, , .		0
123	Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2018, 36, 571-571.	0.8	0
124	Abstract 2953: Overall survival results of the single-institution molecular screening MOSCATO trial in hard-to-treat advanced cancers. , 2018, , .		0
125	A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. Annals of Oncology, 2017, 28, 1523-1531.	0.6	80
126	Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events. Journal of Biopharmaceutical Statistics, 2017, 27, 1043-1053.	0.4	1

#	Article	IF	Citations
127	Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region. Public Health, 2017, 149, 81-88.	1.4	7
128	Authorsâ€™ Reply to Schoenfeld: â€œProgression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumorsâ€. Drugs, 2017, 77, 1139-1140.	4.9	1
129	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discovery, 2017, 7, 586-595.	7.7	554
130	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. Drugs, 2017, 77, 713-719.	4.9	33
131	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncology, The, 2017, 18, 52-62.	5.1	225
132	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. Journal of the National Cancer Institute, 2017, 109, .	3.0	37
133	Evaluating Personalized Medicine in Multi-marker Multi-treatment Clinical Trials: Accounting for Heterogeneity. , 2017, , 125-149.		0
134	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). European Journal of Cancer, 2017, 85, 133-145.	1.3	84
135	Predictors of responses to immune checkpoint blockade in advanced melanoma. Nature Communications, 2017, 8, 592.	5.8	166
136	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clinical Cancer Research, 2017, 23, 6101-6112.	3.2	102
137	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€"Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24,	2.4	530
138	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469
139	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. European Journal of Cancer, 2017, 87, 122-130.	1.3	120
140	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 2017, 377, 1836-1846.	13.9	1,052
141	Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. BMC Medical Research Methodology, 2017, 17, 83.	1.4	10
142	Identification of biomarkerâ€byâ€treatment interactions in randomized clinical trials with survival outcomes and highâ€dimensional spaces. Biometrical Journal, 2017, 59, 685-701.	0.6	26
143	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy. Annals of Oncology, 2017, 28, v68.	0.6	3
144	Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial. Annals of Oncology, 2017, 28, vi55.	0.6	0

#	Article	IF	Citations
145	Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study. , 2017, , .		8
146	Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. Cancer Research, 2017, 77, S3-01-S3-01.	0.4	7
147	Fatigue and health behaviors in cancer survivors: A cross-sectional population based study.. Journal of Clinical Oncology, 2017, 35, 10069-10069.	0.8	1
148	Tutorial in Joint Modeling and Prediction: A Statistical Software for Correlated Longitudinal Outcomes, Recurrent Events and a Terminal Event. Journal of Statistical Software, 2017, 81, .	1.8	31
149	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2017, 35, 575-575.	0.8	1
150	Abstract 388: A benchmark study for identifying cancer drivers in the non-coding part of the genome. , 2017, , .		1
151	Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. , 2017, , .		0
152	Surrogate endpoints for overall survival in loco-regionally advanced nasopharyngeal carcinoma: Results from the individual patient data meta-analysis MAC-NPC2. Annals of Oncology, 2016, 27, vi328.	0.6	1
153	Joint Model for Left-Censored Longitudinal Data, Recurrent Events and Terminal Event: Predictive Abilities of Tumor Burden for Cancer Evolution With Application to the FFCD 2000â€“05 Trial. Biometrics, 2016, 72, 907-916.	0.8	28
154	Empirical extensions of the lasso penalty to reduce the false discovery rate in highâ€dimensional Cox regression models. Statistics in Medicine, 2016, 35, 2561-2573.	0.8	74
155	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
156	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Science Translational Medicine, 2016, 8, 369ra177.	5.8	33
157	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology, 2016, 2, 1040.	3.4	73
158	Concordance between HERâ€2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients. Molecular Oncology, 2016, 10, 1430-1436.	2.1	6
159	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Annals of Oncology, 2016, 27, 1860-1866.	0.6	45
160	Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. Annals of Oncology, 2016, 27, 2160-2167.	0.6	33
161	Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. BMC Medical Research Methodology, 2016, 16, 37.	1.4	28
162	New insights into the evaluation of randomized controlled trials for rare diseases over a longâ€term research horizon: a simulation study. Statistics in Medicine, 2016, 35, 3245-3258.	0.8	8

#	Article	IF	Citations
163	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. Cancer Research, 2016, 76, 264-274.	0.4	21
164	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. JAMA Oncology, 2016, 2, 217.	3.4	21
165	Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Annals of Oncology, 2016, 27, 1029-1034.	0.6	39
166	Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma. American Journal of Pathology, 2016, 186, 435-445.	1.9	17
167	Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial. , 2016, , .		10
168	Abstract P1-14-01: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive,PIK3CAmutant andPIK3CAwild-type primary breast cancer â€“ NeoPHOEBE. , 2016, , .		4
169	Abstract P3-10-03: Receipt of breast cancer risk assessment and personalized prevention information among women diagnosed with a benign breast lesion (BBL) in a one stop breast unit: A prospective assessment. , 2016, , .		1
170	Abstract S1-03: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy. Cancer Research, 2016, 76, S1-03-S1-03.	0.4	20
171	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. PLoS ONE, 2016, 11, e0154009.	1.1	27
172	Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data. Oncotarget, 2016, 7, 3002-3017.	0.8	19
173	Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis. , 2016, , .		0
174	Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 680-686.	0.2	6
175	467 Radiomics to identify HER2 amplification or mutation in metastatic patients with solid tumors prospectively enrolled in MOSCATO-01. European Journal of Cancer, 2015, 51, S101.	1.3	2
176	3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC). European Journal of Cancer, 2015, 51, S647-S648.	1.3	6
177	3127 Prognostic value of texture analysis in advanced non-small cell lung cancer (NSCLC). European Journal of Cancer, 2015, 51, S645-S646.	1.3	4
178	Prediction of treatment benefit in high-dimensional cox models via gene signatures in randomized clinical trials. Trials, 2015, 16, .	0.7	0
179	A Dual Model for Prioritizing Cancer Mutations in the Non-coding Genome Based on Germline and Somatic Events. PLoS Computational Biology, 2015, 11, e1004583.	1.5	17
180	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Annals of Oncology, 2015, 26, 873-879.	0.6	151

#	Article	IF	Citations
181	A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer. Statistical Methods in Medical Research, 2015, 24, 711-729.	0.7	37
182	Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. Public Health Genomics, 2015, 18, 349-358.	0.6	14
183	Precision medicine for metastatic breast cancerâ€"limitations and solutions. Nature Reviews Clinical Oncology, 2015, 12, 693-704.	12.5	272
184	A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort. Breast Cancer Research and Treatment, 2015, 150, 415-426.	1.1	10
185	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. JAMA Oncology, 2015, 1, 448.	3.4	482
186	Mining the coding and non-coding genome for cancer drivers. Cancer Letters, 2015, 369, 307-315.	3.2	15
187	Reply to V.P. RetÃ¨l et al, D. Gauchan et al, and C. Rahilly-Tierney et al. Journal of Clinical Oncology, 2015, 33, 1629-1630.	0.8	0
188	Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC).. Journal of Clinical Oncology, 2015, 33, 516-516.	0.8	5
189	Abstract PD3-7: Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analyses in breast cancer. , 2015, , .		0
190	Predictive ability of tumor growth modeling for overall survival in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14619-e14619.	0.8	0
191	Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. BMC Genomics, 2014, 15, 1008.	1.2	52
192	Statistical methods applied to omics data. Current Opinion in Oncology, 2014, 26, 576-583.	1.1	4
193	International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Research, 2014, 16, R43.	2.2	43
194	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet, The, 2014, 383, 2127-2135.	6.3	1,701
195	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2014, 15, 406-414.	5.1	703
196	Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3513-3519.	0.8	28
197	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Annals of Oncology, 2014, 25, 1959-1965.	0.6	206
198	Testing the treatment effect on competing causes of death in oncology clinical trials. BMC Medical Research Methodology, 2014, 14, 72.	1.4	7

#	Article	IF	Citations
199	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Annals of Oncology, 2014, 25, 1544-1550.	0.6	1,022
200	Incidence and mortality rates of breast and gynecologic cancers and human development index in the pan-American region.. Journal of Clinical Oncology, 2014, 32, 1596-1596.	0.8	2
201	Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period.. Journal of Clinical Oncology, 2014, 32, 1082-1082.	0.8	0
202	Evaluation of PI3K-pathwayâ€"activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.. Journal of Clinical Oncology, 2014, 32, 11060-11060.	0.8	0
203	Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. Genomics Data, 2013, 1, 7-10.	1.3	6
204	A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Molecular Oncology, 2013, 7, 987-999.	2.1	36
205	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 2013, 31, 860-867.	0.8	1,342
206	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1667-1670.	3.0	78
207	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. European Journal of Cancer, 2013, 49, 1565-1577.	1.3	136
208	Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncology, The, 2013, 14, 619-626.	5.1	203
209	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1600-1607.	3.0	133
210	Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. European Journal of Cancer, 2013, 49, 1882-1888.	1.3	5
211	Genomic grade adds prognostic value in invasive lobular carcinoma. Annals of Oncology, 2013, 24, 377-384.	0.6	52
212	Omics-based clinical trial designs. Current Opinion in Oncology, 2013, 25, 289-295.	1.1	16
213	Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Annals of Oncology, 2013, 24, 647-654.	0.6	117
214	Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer. Journal of the National Cancer Institute, 2013, 105, 960-967.	3.0	138
215	Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis. PLoS ONE, 2013, 8, e62451.	1.1	27
216	Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer. PLoS ONE, 2013, 8, e66848.	1.1	21

#	Article	IF	Citations
217	Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer â€“ NeoPHOEBE. Cancer Research, 2013, 73, OT2-6-08-OT2-6-08.	0.4	2
218	Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research, 2013, 73, S1-05-S1-05.	0.4	20
219	CD4+ follicular helper T cell infiltration predicts breast cancer survival. Journal of Clinical Investigation, 2013, 123, 2873-2892.	3.9	813
220	Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis.. Journal of Clinical Oncology, 2013, 31, 610-610.	0.8	1
221	PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer. PLoS ONE, 2013, 8, e53292.	1.1	80
222	Abstract P6-05-12: Comprehensive molecular analysis of estrogen receptor positive breast cancer to determine clinically actionable alterations. , 2013, , .		0
223	Abstract PD6-5: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data. , 2013, , .		0
224	Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. Annals of Oncology, 2012, 23, 2059-2064.	0.6	12
225	Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling. Clinical Cancer Research, 2012, 18, 1341-1351.	3.2	303
226	Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment. Clinical Cancer Research, 2012, 18, 1004-1014.	3.2	46
227	Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis. Journal of Clinical Oncology, 2012, 30, 1996-2004.	0.8	194
228	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Annals of Oncology, 2012, 23, 2997-3006.	0.6	233
229	Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. The Cochrane Library, 2012, , CD004569.	1.5	18
230	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Projectâ€”Part 2). Journal of Thoracic Oncology, 2012, 7, 1490-1502.	0.5	69
231	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncology, The, 2012, 13, e240-e248.	5.1	64
232	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. European Respiratory Journal, 2012, 39, 172-179.	3.1	43
233	Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 441-448.	1.4	49
234	Abstract P4-09-05: Microarray anlyses of breast cancers identify CH25H, a cholesterol gene, as a potential marker and target for late metastatic reccurences.. , 2012, , .		1

#	Article	IF	Citations
235	Abstract P3-04-10: Comparison between RNA-Seq and Affymetrix gene expression data. , 2012, , .		1
236	Abstract P1-07-08: Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer.. , 2012, , .		1
237	Abstract S4-4: Independent validation of Genomic Grade in the BIG 1-98 study. , 2012, , .		2
238	Abstract P3-05-03: Characterization of PIK3CA mutations in lobular breast cancer. , 2012, , .		0
239	Abstract P6-07-14: Mutational and transcriptomic characterization of breast cancer (BC) arising in young patients (pts) and during pregnancy and their associations with long-term outcome. , 2012, , .		0
240	Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics, 2011, 11, 171-182.	1.5	124
241	IntÃ©gration des marqueurs pronostiques et prÃ©dictifs dans les essais cliniques. Annales De Pathologie, 2011, 31, S18-S19.	0.1	0
242	Biomarker studies: a call for a comprehensive biomarker study registry. Nature Reviews Clinical Oncology, 2011, 8, 171-176.	12.5	106
243	Multidimensionality of microarrays: Statistical challenges and (im)possible solutions. Molecular Oncology, 2011, 5, 190-196.	2.1	21
244	Activation of the phosphatidylinositol 3â€²-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. Human Pathology, 2011, 42, 1727-1739.	1.1	20
245	HER2-Positive Circulating Tumor Cells in Breast Cancer. PLoS ONE, 2011, 6, e15624.	1.1	176
246	Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 1006-1015.	9.5	62
247	Time to move forward from â€œfirst-generationâ€•prognostic gene signatures in early breast cancer. Breast Cancer Research and Treatment, 2011, 128, 643-645.	1.1	1
248	Multiple testing of treatmentâ€•effectâ€•modifying biomarkers in a randomized clinical trial with a survival endpoint. Statistics in Medicine, 2011, 30, 1502-1518.	0.8	11
249	DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Molecular Medicine, 2011, 3, 726-741.	3.3	210
250	Research Highlights. Pharmacogenomics, 2011, 12, 9-13.	0.6	1
251	Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica, 2011, 96, 1106-1112.	1.7	33
252	Multifactorial Approach to Predicting Resistance to Anthracyclines. Journal of Clinical Oncology, 2011, 29, 1578-1586.	0.8	169

#	Article	IF	Citations
253	Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. Endocrine-Related Cancer, 2011, 18, 721-730.	1.6	8
254	Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib. Blood, 2011, 118, 1877-1877.	0.6	10
255	Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT).. Journal of Clinical Oncology, 2011, 29, 556-556.	0.8	3
256	Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer.. Journal of Clinical Oncology, 2011, 29, 7004-7004.	0.8	3
257	Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival. , 2011, , .		0
258	Abstract LB-180: Epigenetic portraits of human breast cancers. , 2011, , .		0
259	Genomic grade: Feasibility in routine practice and influence on treatment decision in early breast cancer.. Journal of Clinical Oncology, 2011, 29, 606-606.	0.8	15
260	Use of genomic grade index to improve tumor grading of invasive lobular breast carcinoma.. Journal of Clinical Oncology, 2011, 29, 535-535.	0.8	0
261	PD03-10: Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis.. , 2011, , .		0
262	S1-6: Characterization of Breast Cancer Distant Metastasis Based on Outcome over Time Using a Gene Expression Profiling Approach and Identification of Pathway Activities of Late Relapse.. , 2011, , .		3
263	P4-07-14: Circulating Tumor Cells (CTCs) Detection and HER2 Profiling by CellSearchÂ® in Non-Metastatic Breast Cancer: An International Ring Study To Assess Inter-Reader Variability.. , 2011, , .		0
264	P1-02-05: Invasive Lobular Carcinoma â€“ A Luminal Breast Cancer Histotype Enriched for Epithelial-to-Mesenchymal Transition Features.. , 2011, , .		0
265	Clinical Usefulness of Microarrays for Cancer Prognosis in 2010â€"Letter. Clinical Cancer Research, 2010, 16, 6180-6180.	3.2	2
266	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. JAMA - Journal of the American Medical Association, 2010, 303, 1729.	3.8	711
267	CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. Oncologist, 2009, 14, 1182-1188.	1.9	59
268	Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array. Clinical Cancer Research, 2009, 15, 441-451.	3.2	300
269	Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2009, 27, 5965-5971.	0.8	23
270	Natural Killer Cell IFN-Î³ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumorâ€"Bearing Patients. Cancer Research, 2009, 69, 3563-3569.	0.4	181

#	Article	IF	Citations
271	Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk. Carcinogenesis, 2009, 30, 763-768.	1.3	37
272	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncology, The, 2009, 10, 341-350.	5.1	138
273	Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncology, The, 2009, 10, 381-390.	5.1	55
274	An exonic expression profile for breast cancer diagnosis of fine needle aspiration biopsies.. , 2009, , .		0
275	Investigating trial and treatment heterogeneity in an individual patient data metaâ€analysis of survival data by means of the penalized maximum likelihood approach. Statistics in Medicine, 2008, 27, 1894-1910.	0.8	37
276	Variants in DNA doubleâ€strand break repair and DNA damageâ€response genes and susceptibility to lung and head and neck cancers. International Journal of Cancer, 2008, 123, 457-463.	2.3	23
277	Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Molecular Oncology, 2008, 1, 425-430.	2.1	47
278	Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Annals of Oncology, 2008, 19, 315-320.	0.6	31
279	Individual- and trial-level surrogacy in colorectal cancer. Statistical Methods in Medical Research, 2008, 17, 467-475.	0.7	65
280	Predictive value of MRP2, p53, bcl2 and topoisomerase II immunostainings for the efficacy of anthracyclines-based adjuvant chemotherapy in breast cancer: Results from two randomized trials. Journal of Clinical Oncology, 2008, 26, 616-616.	0.8	1
281	High resolution oligonucleotide array-CGH to identify therapeutic targets in breast cancer. Journal of Clinical Oncology, 2008, 26, 547-547.	0.8	0
282	Association between prothrombin rate, alpha-fetoprotein changes and survival of patients with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology, 2008, 26, 15507-15507.	0.8	0
283	Association of critical losses in X chromosome with melanoma progression: An EORTC Melanoma group study. Journal of Clinical Oncology, 2008, 26, 9000-9000.	0.8	0
284	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 5218-5224.	0.8	321
285	Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Annals of Oncology, 2007, 18, 1043-1050.	0.6	58
286	Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Annals of Oncology, 2007, 18, 1477-1483.	0.6	73
287	Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 â€˜triple-negativeâ€™ breast cancers. Annals of Oncology, 2007, 18, 1285-1286.	0.6	67
288	Sodium/Iodide Symporter (NIS) Gene Expression Is the Limiting Step for the Onset of Thyroid Function in the Human Fetus. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 70-76.	1.8	74

#	Article	IF	Citations
289	Five-Gene Signature in Nonâ€"Small-Cell Lung Cancer. New England Journal of Medicine, 2007, 356, 1581-1583.	13.9	3
290	Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancers. Carcinogenesis, 2007, 28, 1731-1739.	1.3	65
291	Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. , 2007, , CD004569.		26
292	Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis?. European Journal of Cancer, 2007, 43, 745-751.	1.3	96
293	Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncology, The, 2007, 8, 994-1000.	5.1	103
294	S15 Interpretation of microarray data in cancer: a statistical viewpoint. European Journal of Cancer, Supplement, 2007, 5, 11.	2.2	0
295	Expression of erythropoietin and its receptor in neuroblastomas. Cancer, 2007, 110, 1096-1106.	2.0	26
296	Interpretation of microarray data in cancer. British Journal of Cancer, 2007, 96, 1155-1158.	2.9	84
297	Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. Journal of Clinical Oncology, 2007, 25, 4512-4512.	0.8	47
298	Surrogate endpoints for overall survival (OS) in head and neck squamous cell carcinoma (HNSCC): Evaluation using individual data of 23,737 patients. Journal of Clinical Oncology, 2007, 25, 6035-6035.	0.8	1
299	Cxcr4 expression and risk of bone metastasis in patients with early breast cancer. Journal of Clinical Oncology, 2007, 25, 10610-10610.	0.8	1
300	Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in an hospital pharmacy. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 64, 92-98.	2.0	18
301	HEX, PAX-8 and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism. Clinical Endocrinology, 2006, 64, 060301024427002.	1.2	17
302	Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. Modern Pathology, 2006, 19, 1170-1180.	2.9	25
303	In reply to Drs. Huncharek and Kupelnick. International Journal of Radiation Oncology Biology Physics, 2006, 65, 958-959.	0.4	4
304	Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome. Journal of the National Cancer Institute, 2006, 98, 472-482.	3.0	457
305	A new genomic approach to describe the natural history of node negative breast cancer patients. Journal of Clinical Oncology, 2006, 24, 10058-10058.	0.8	0
306	Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Annals of Oncology, 2005, 16, 1906-1914.	0.6	59

#	Article	IF	Citations
307	Validation of Microarray Data by Quantitative Reverse-Transcriptase Polymerase Chain Reaction. Journal of Clinical Oncology, 2005, 23, 9439-9440.	0.8	5
308	Bias in the estimation of false discovery rate in microarray studies. Bioinformatics, 2005, 21, 3865-3872.	1.8	70
309	Meta-analysis when only the median survival times are known: A comparison with individual patient data results. International Journal of Technology Assessment in Health Care, 2005, 21, 119-125.	0.2	124
310	Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet, The, 2005, 365, 488-492.	6.3	924
311	Prediction of cancer outcome with microarrays. Lancet, The, 2005, 365, 1683.	6.3	14
312	Prediction of cancer outcome with microarrays. Lancet, The, 2005, 365, 1684-1685.	6.3	15
313	False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics, 2005, 21, 3017-3024.	1.8	410
314	Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses. Journal of Clinical Epidemiology, 2005, 58, 238-245.	2.4	29
315	Follicular Thyroid Tumors with the PAX8-PPARÎ³1 Rearrangement Display Characteristic Genetic Alterations. American Journal of Pathology, 2005, 167, 223-231.	1.9	79
316	Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis. Journal of Clinical Oncology, 2004, 22, 3766-3775.	0.8	339
317	Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Nonâ€“Small-Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2004, 292, 470.	3.8	305
318	Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer, 2004, 100, 28-35.	2.0	88
319	Textbook of Clinical Trials in Oncology. , 0, , .		6